V. Benade

发表

A sensitive and selective quantification of catecholamine neurotransmitters in rat microdialysates by pre-column dansyl chloride derivatization using liquid chromatography-tandem mass spectrometry.

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Approach to reduce the non-specific binding in microdialysis

R. Nirogi, V. Kandikere, R. Saralaya, 2012, Journal of Neuroscience Methods.

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

A. Atri, R. Nirogi, J. Cummings, 2022, Alzheimer's & dementia.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol.

S. Vishwakarma, B. Thippeswamy, N. Kulkarni, 2010, European journal of pharmacology.

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2019, Journal of medicinal chemistry.

Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2022, Clinical Drug Investigation.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2021, Psychopharmacology.

Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2015, European journal of medicinal chemistry.

Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2012, Brain Research.

1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2021, ChemMedChem.

Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders

R. Nirogi, G. Bhyrapuneni, Arunkumar Manoharan, 2021, Journal of psychopharmacology.

SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2019, Behavioural pharmacology.

Simultaneous monitoring of electroencephalographic characteristics in animals subjected to behavioral tests: a preclinical investigation

R. Nirogi, G. Bhyrapuneni, V. Benade, 2017, Behavioural pharmacology.

Mechanistic evaluation of tapentadol in reducing the pain perception using in‐vivo brain and spinal cord microdialysis in rats

R. Nirogi, R. Ponnamaneni, G. Bhyrapuneni, 2017, European journal of pharmacology.

A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system

Koteshwara Mudigonda, Vishwottam Kandikere, Ramakrishna Nirogi, 2009, Journal of Neuroscience Methods.

Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats

K. Mukkanti, R. Nirogi, V. Kandikere, 2012, European Journal of Drug Metabolism and Pharmacokinetics.

LC-MS/MS method for the quantification of almotriptan in dialysates: application to rat brain and blood microdialysis study.

R. Nirogi, V. Kandikere, S. Srikakolapu, 2013, Journal of pharmaceutical and biomedical analysis.

Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2023, Biomolecules.

Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2017, Journal of medicinal chemistry.

Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2018, Journal of medicinal chemistry.

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2021, Journal of medicinal chemistry.

Therapeutic Potential of 5-HT6 Antagonist SB399885 in Traumatic Stress Disorder

R. Nirogi, A. Shinde, V. Benade, 2014, Drug Research.

Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2022, International journal of geriatric psychiatry.

Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2023, European journal of pharmacology.

Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats

R. Nirogi, N. Muddana, A. Shinde, 2016, Behavioural pharmacology.

Effect of Bauhinia variegate Bark Extract on Blood Glucose Level in Normal and Alloxanised Diabetic Rats

R. Karadi, A. Taranalli, V. Benade, 2009 .

SUVN-502, POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST: PROOF-OF-CONCEPT STUDY DESIGN IN MODERATE ALZHEIMER’S DISEASE PATIENTS

R. Nirogi, K. Mudigonda, A. Shinde, 2016, Alzheimer's & Dementia.

Suvn-g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models

R. Nirogi, Arunkumar Manoharan, A. Shinde, 2015, Alzheimer's & Dementia.

Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol.

S. Vishwakarma, B. Thippeswamy, N. Kulkarni, 2010, European journal of pharmacology.

Hits and misses with animal models of narcolepsy and the implications for drug discovery

R. Nirogi, V. Goyal, V. Benade, 2024, Expert opinion on drug discovery.